Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q3 FY20 results · Oct–Dec 2019
Sun Pharma Advanced Research Company reported revenue from operations of ₹19.60 crore (down 1.4% from Q3 FY19) and net loss of ₹55.51 crore for Q3 FY20 (Oct–Dec 2019), on a standalone basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 19.60 | 19.88 | −1.4% | 17.19 | +14.0% |
| Other income | 0.71 | 3.28 | −78.4% | 2.26 | −68.6% |
| Total income | 20.31 | 23.16 | −12.3% | 19.45 | +4.4% |
| Profit before tax | (55.51) | (69.02) | Loss narrowed | (63.16) | Loss narrowed |
| Net profit for the period | (55.51) | (69.02) | Loss narrowed | (63.16) | Loss narrowed |
| EPS, basic (₹) | (2.12) | (2.72) | Loss narrowed | (2.41) | Loss narrowed |
| Net margin (%) | -283.2 | -347.2 | -367.4 |
Standalone
- Filed with BSE
- 01 Feb 2020, 15:57 IST
- Board meeting
- 31 Jan 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE